Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — FY2023 Earnings Presentation
29 slides from Monash Ivf's earnings presentation, Aug 22, 2023
Slide 1: FY23 Results Presentation
e @ Monash IVF Group FY23 Results Presentation 22 August 2023
Slide 2: Disclaimer
Monash IVF Group |FY23 Results Presentation @ Monash IVF Group Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF's activities as a
Slide 3: Executive summary
Page 3 Executive summary • • • Group • • • Australia International • • • • FY23 • Results • • • • • • • • Invest • • in • • future • growth •
Slide 4: Robust market growth in 2H23 driven by underlying structural tailwinds
Page 4 Robust market growth in 2H23 driven by underlying structural tailwinds Advanced • maternal age o o • • Innovation/ technology • • • Awareness and support • • New services • Patient segments
Slide 5: Industry volumes - ARS Australia
Page 5 Industry volumes - ARS Australia 1H20 2H20 1H21 2H21 1H22 2H22 1H23 2H23 60.0% 43.9% 22,024 20,655 21,820 40.0% 16,528 17,440 15,302 23.8% 20.0% 5.6% 24,069 24,924 23,267 3.6% 18,584 19,436 19,447 0.1% 0.0% -6.2% -6.6% FY18 FY19 FY20 FY21 FY22 FY23 -20.0% -12.3% Jul-Dec Jan-Jun • • • • •
Slide 6: MVF market share - ARS Australia
Page 6 MVF market share - ARS Australia • o o o • • • 22.7% 21.3% 20.4% 21.0% FY20 FY21 FY22 FY23
Slide 7: Financial results
| | 9°) = inanc F results @ Monash IVF Group
Slide 8: FY23 Revenue Analysis
Page 8 FY23 Revenue Analysis 220 3.0 210 2.0 2.6 5.4 200 7.2 $M 2.2 3.3 213.6 190 180 192.3 170 FY22 Industry Decline Organic Market Share Growth Acquisitions Price & Mix International Ultrasound DSU & Other FY23 • o o o • • •
Slide 9: FY23 EBITDA Analysis
Page 9 FY23 EBITDA(1) Analysis 55 1.0 1.3 0.7 1.0 5.0 5.3 50 4.9 $M 45 53.1 53.4 48.1 48.5 40 43.2 35 FY22 Reported EBITDA(1) Non-regular items(2) FY22 Underlying EBITDA(1) MVF Share Growth Price, Mix & Cost Base Industry Decline Sub Total International Ultrasound FY23 Underlying EBITDA(1) Non-regul
Slide 10: FY23 Profit & Loss Overview
Page 10 FY23 Profit & Loss Overview • (1)(2)(3) • o o o o o • • •
Slide 11: FY23 Cashflow Overview
Page 11 FY23 Cashflow Overview • FY23 FY22 • o o o o • • • • •
Slide 12: Balance Sheet Overview
Page 12 Balance Sheet Overview • o o • 30 June 22 • • •
Slide 13: Operational Review
Operational Review
Slide 14: Compelling Doctor Value Proposition continues to attract new doctors
Page 14 Compelling Doctor Value Proposition continues to attract new doctors • • • 30 25 25 • 20 15 12 11 10 7 6 • 5 2 0 • FY19 FY20 FY21 FY22 FY23 FY24
Slide 15: Investing in the future with new and upgraded clinic infrastructure
Page 15 Investing in the future with new and upgraded clinic infrastructure • • • • • • • • •
Slide 16: Acquisitions update
Page 16 Acquisitions update ART Associates Queensland PIVET (Completed in September 2022) (Completed in May 2023) • • • • • • • • • • • • • • • • •
Slide 17: Science and technology to drive ongoing improvements in success rates
Page 17 Science and technology to drive ongoing improvements in success rates • • 40.0% 39.0% 38.7% 38.0% 38.0% 37.0% 37.0% 36.4% 36.0% 35.0% 34.7% 34.0% 33.0% 32.6% 32.0% 2018 2019 2020 2021 2022 2023 (Jan-Mar)
Slide 18: Monash IVF is well positioned to capitalise on growth in genetics
Page 18 Monash IVF is well positioned to capitalise on growth in genetics • Monash IVF is uniquely placed to capitalise on growth • • • • • Monash • IVF is uniquely placed to capitalise on growth o • • • o o •
Slide 19: Investing in Brand & Marketing and our People
Page 19 Investing in Brand & Marketing and our People • • • • • • • • •
Slide 20: Ultrasound recovery gained momentum in FY23
Page 20 Ultrasound recovery gained momentum in FY23 • • • •
Slide 21: ARS International
Page 21 ARS International • • • • • • • • • • • • • • •
Slide 22: Strategy and Outlook
Strategy and Outlook
Slide 23: The most admired reproductive care provider in the world
Page 23 The most admired reproductive care provider in the world
Slide 24: Outlook
Page 24 Outlook We continue to believe and are optimistic that there is a fundamental shift in • Domestic IVF and Ultrasound patient pricing will increase by 5%-8% the Community and the mindset of our patient cohort with greater focus on during 1H24 across all State based markets which is anticipate
Slide 25: Appendices
Appendices e @ Monash IVF Group
Slide 26: Treatment Mix
Monash IVF Group |FY23 Results Presentation Page 26 Treatment Mix Stimulated cycles 10,323 9,783 5.5% Cancelled cycles 1167 1,202 (29%) Frozen embryo transfers TA04 7,086 45% Total Australian Patient Treatments 18,894 18,071 46% Menu VE reac Stimulated cycles 1149 19.9% Cancelled cycles 46 si (25.8%
Slide 27: FY23 Earnings Reconciliation
Page 27 FY23 Earnings Reconciliation • • •
Slide 28: Overview of Monash IVF Group
Page 28 Overview of Monash IVF Group
Slide 29: Slide 29